Browsing Tag
B7-H3
7 posts
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
NK cell immunotherapy moves toward solid tumors as GT Biopharma files IND for GTB-5550 TriKE
Find out how NK cell immunotherapy is moving into solid tumors as GT Biopharma files an IND for its B7-H3-targeted TriKE GTB-5550.
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial shows
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
InnoCare Pharma receives Chinese IND clearance for novel B7-H3 targeted ADC ICP-B794 to treat solid tumors
InnoCare Pharma gains Chinese IND approval for ICP-B794, a novel B7-H3 targeted ADC for solid tumors including lung and prostate cancer.